軟部肉腫市場- 世界の産業規模、シェア、動向、機会、予測、治療タイプ別、エンドユーザー別、地域別、競合別、2019年～2029年

軟部肉腫の世界市場は、2023年に13億6,000万米ドルと評価され、2029年までのCAGRは8.45%で、予測期間中に力強い成長が予測されています。

軟部肉腫の主な治療法は手術であり、腫瘍または患部の一部を切除します。放射線療法も腫瘍を縮小または根絶するために、手術との併用または単独の治療として採用されることがあります。化学療法は、他の治療法の効果を高めるための補助療法として一般的に用いられます。軟部肉腫の予後は、がんの種類、部位、病期によって大きく異なります。一般に、早期診断と迅速な治療がより良好な結果をもたらします。治療法の選択肢と予後は進化し、改善され続けているため、この分野の進歩を常に把握しておくことは極めて重要です。臨床試験は、最先端の治療にアクセスし、軟部肉腫に対する最適なアプローチについてさらなる洞察を得る上で重要な役割を果たします。軟部肉腫は、手術、放射線療法、および/または化学療法を組み合わせて効果的に治療することができます。軟部肉腫の予後は、がんの種類、部位、病期など様々な要因によって異なります。現在進行中の臨床試験と調査により、治療戦略を改良し、治療成績と生活の質を高めるための貴重な情報が得られます。手術、放射線療法、化学療法が軟部肉腫の最も一般的な治療法であるが、免疫療法、分子標的治療、漢方薬などの代替療法も有効です。また、食事療法や運動療法を含む生活習慣の改善は、軟部肉腫の発症リスクを低減し、回復プロセスを支援するのに役立ちます。

主な市場促進要因

がん患者の増加

新しく革新的な治療法の開発

新しい肉腫治療薬の承認数の増加

提携や買収などの主要戦略の採用の増加

主な市場課題

治療費の高騰

軟部肉腫治療薬の副作用

主要市場動向

他の治療法のイントロダクション

ヘルスケア意識の高まり

セグメント別洞察

治療タイプ別洞察

エンドユーザー別洞察

地域別洞察

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 臨床試験分析

第6章 軟部肉腫の世界市場展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • 治療タイプ別（標的療法、化学療法、血管新生阻害薬、放射線療法、その他）
  • エンドユーザー別（病院、在宅医療、専門センター、その他）
  • 地域別
  • 企業別（2023年）
• 市場マップ

第7章 北米の軟部肉腫市場展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • 治療タイプ別
  • エンドユーザー別
  • 国別
• 北米：国別分析
  • 米国
  • カナダ
  • メキシコ

第8章 欧州の軟部肉腫市場展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • 治療タイプ別
  • エンドユーザー別
  • 国別
• 欧州国別分析
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン

第9章 アジア太平洋の軟部肉腫市場展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • 治療タイプ別
  • エンドユーザー別
  • 国別
• アジア太平洋地域国別分析
  • 中国
  • インド
  • 日本
  • 韓国
  • オーストラリア

第10章 南米の軟部肉腫市場展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • 治療タイプ別
  • エンドユーザー別
  • 国別
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第11章 中東・アフリカの軟部肉腫市場展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • 治療タイプ別
  • エンドユーザー別
  • 国別
• MEA：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第12章 市場力学

• 促進要因
• 課題

第13章 市場動向と発展

• 合併買収（もしあれば）
• 製品上市（もしあれば）
• 最近の動向

第14章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第15章 競合情勢

• F. Hoffmann-La Roche Ltd.
• Mylan N.V.
• Teva Pharmaceutical Industries Ltd.
• Sanofi S.A.
• Pfizer Inc.
• GSK plc
• Novartis AG
• Bayer AG
• Sun Pharmaceutical Industries Ltd.
• Merck Co., Inc.

第16章 戦略的提言

第17章 免責事項

Global Soft Tissue Sarcoma Market was valued at USD 1.36 Billion in 2023 and is anticipated to project robust growth in the forecast period with a CAGR of 8.45% through 2029. Surgery is typically the primary treatment approach for soft tissue sarcomas, involving the removal of the tumor or a portion of the affected area. Radiation therapy may also be employed to shrink or eradicate the tumor, either in combination with surgery or as a standalone treatment. Chemotherapy is commonly utilized as an adjunctive therapy to enhance the effectiveness of other treatment modalities. The prognosis for soft tissue sarcomas can vary significantly, contingent upon the type, location, and stage of the cancer. Generally, an earlier diagnosis and prompt treatment yield more favorable outcomes. It is crucial to remain up to date with advancements in the field, as treatment options and prognoses continue to evolve and improve. Clinical trials play a critical role in accessing state-of-the-art treatments and gaining further insights into optimal approaches for soft tissue sarcomas. Participation in clinical trials can contribute to improved outcomes and enhanced quality of life for patients with soft tissue sarcomas.Soft tissue sarcomas can be effectively treated by a blend of surgery, radiation therapy, and/or chemotherapy.Prognosis for soft tissue sarcomas depends on various factors, including the type, location, and stage of the cancer. Ongoing clinical trials and research provide valuable information to refine treatment strategies and enhance outcomes and quality of life. While surgery, radiation therapy, and chemotherapy are the most common treatments for soft tissue sarcomas, alternative options such as immunotherapy, targeted therapy, and herbal medicine have demonstrated efficacy in managing the condition. Also, lifestyle modifications, including dietary adjustments and exercise, can help reduce the risk of developing soft tissue sarcomas and assist in the recovery process.

Key Market Drivers

Increase in Cancer Cases

Sarcoma is a type of cancer that can affect various tissues. Soft tissue sarcomas specifically impact the connective, supportive, or surrounding tissues of the body's systems. According to the American Society of Clinical Oncology (ASCO), soft tissue sarcomas account for approximately 1% of all adult cancers. Although more prevalent in children, comprising around 15% of all childhood cancers, it remains a significant concern. Besides, the National Cancer Institute estimates that in 2019, approximately 12,750 cases of soft tissue sarcoma were diagnosed in the United States, with an estimated 5,270 resulting in death. In addition, the American Cancer Society reported approximately 3,600 new cases of bone and joint cancer in 2020, with 2,120 cases among males and 1,480 among females in the United States. On top of that, an estimated 1,720 deaths in the U.S. in 2020 were attributed to bone and joint cancer. Looking ahead, the American Cancer Society projects that approximately 13,590 new cases of soft tissue sarcoma will be diagnosed in 2024. Of these, 7,700 cases are expected among males and 5,890 among females in the United States. It is estimated that around 5,200 individuals (2,760 males and 2,440 females) will succumb to soft tissue sarcomas, according to the same source.

Development of New and Innovative Therapies

The development of new and innovative therapies is playing a crucial role in boosting the growth of the Soft Tissue Sarcoma (STS) market. Soft tissue sarcomas are a diverse group of rare cancers that develop in the connective tissues of the body, including muscles, fat, blood vessels, and nerves. Historically, treatment options for STS have been limited, but advancements in research and the introduction of novel therapies are changing the landscape. The introduction of new therapies, such as targeted therapies, immunotherapies, and precision medicine approaches, provides patients with a broader range of treatment options beyond traditional approaches like surgery, radiation, and chemotherapy. Innovative therapies are designed to specifically target the underlying genetic and molecular characteristics of STS tumors. This personalized approach can lead to improved patient outcomes, including better response rates and longer survival. Advanced diagnostics and biomarker testing enable the identification of specific mutations or genetic markers that guide treatment decisions. This allows for more individualized and effective treatment plans. Advances in understanding the genetic mutations driving STS have led to the development of targeted therapies that specifically inhibit the signaling pathways responsible for tumor growth.

Rise In the Number of Product Approval for New Sarcoma Drugs

The increase in the number of approved products for new sarcoma drugs has contributed to the growth of the sarcoma drugs market. For example, in May 2020, Bristol Myers Squibb, a pharmaceutical company, announced the approval of Pomalyst (pomalidomide) by the U.S. Food and Drug Administration (FDA). This approval was specifically for patients with AIDS-related Kaposi sarcoma whose disease has become resistant to highly active antiretroviral therapy (HAART), or for patients with Kaposi sarcoma who are HIV-negative.

The approval of new sarcoma drugs adds diversity to the available treatment options. Different types of STS require tailored approaches, and a broader range of approved drugs enables healthcare providers to choose the most suitable treatment for each patient. New drugs that demonstrate efficacy in clinical trials can lead to improved survival rates and disease control, positively impacting the overall prognosis for STS patients. The approval of new sarcoma drugs encourages pharmaceutical companies and researchers to invest in innovative research, which can lead to the development of even more effective treatments. Regulatory approval allows a broader patient population to access the newly approved drugs, reaching more patients in need of effective therapies.

Rise In Adoption of Key Strategies Such as Collaboration and Acquisition

The rise in adoption of key strategies, such as collaboration, acquisition, agreement, and partnership, by the sarcoma drugs industry is driving the growth of the market. For example, in March 2021, Phio Pharmaceuticals Corp., a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL) therapeutic platform, announced a clinical development collaboration with AgonOx, Inc. The collaboration aims to develop novel T cell-based cancer immunotherapies using Phio's lead INTASYL-based product candidate, PH-762, and AgonOx's "double positive" (DP) tumor-infiltrating lymphocyte (TIL) technology. Collaborative efforts can lead to the exploration of combination therapies, where different companies contribute complementary treatment approaches that, when combined, yield more effective results. Partnering with or acquiring companies with advanced technologies can lead to the development of innovative drug delivery methods, diagnostic tools, and personalized treatment approaches.

Collaboration can expedite research efforts by allowing companies to share data, insights, and resources. This accelerates the identification of potential targets and the development of new therapies. Collaborative efforts can lead to larger and more diverse clinical trials, which provide a more comprehensive evaluation of the safety and efficacy of potential STS treatments. Companies that collaborate or acquire specialized partners may benefit from streamlined regulatory pathways, leading to faster approvals and market entry for new therapies.

Key Market Challenges

High Cost of Treatments

High treatment costs can limit patient access to effective therapies, especially for individuals without adequate insurance coverage or financial resources. This can lead to delayed or suboptimal treatment, negatively impacting patient outcomes. The high out-of-pocket costs associated with STS treatments can place a significant financial burden on patients and their families, potentially leading to financial hardship and reduced quality of life. High treatment costs can attract public and regulatory scrutiny, leading to pricing pressure and potential limitations on reimbursement and coverage. The substantial costs associated with treatment methods hinder market growth. Several treatments for this disease are expensive, posing challenges for individuals, particularly those in rural areas. Consequently, this becomes a significant obstacle for the market. The rising expenses of radiotherapy and chemotherapy might impede the growth of the soft tissue sarcoma treatment market in the forecast period.

Side-Effects of Soft Tissue Sarcoma Drugs

The presence of significant side effects associated with Soft Tissue Sarcoma (STS) drugs can hinder the growth of the STS market. Side effects can impact patient quality of life, influence treatment decisions, and contribute to challenges in patient adherence and acceptance of treatments. Severe side effects can lead to decreased patient quality of life, affecting their ability to perform daily activities, work, and engage in social interactions. This can discourage patients from pursuing or continuing treatment. Patients experiencing intolerable side effects might choose to discontinue treatment prematurely, potentially reducing the effectiveness of the therapy and hindering positive treatment outcomes. Elderly or frail patients might be more susceptible to side effects, limiting the use of certain drugs in this population and potentially reducing the market demand.

Key Market Trends

Introduction of Other Therapies

The availability of many therapies offers healthcare providers a broader range of options to tailor treatment plans based on the specific subtype, stage, and characteristics of each patient's STS. With a variety of therapies to choose from, physicians can personalize treatment approaches, optimizing the chance of positive responses and minimizing adverse effects. Different STS subtypes have varying responses to treatments. The introduction of multiple therapies can help address unmet medical needs for subtypes that lack effective treatment options. A multitude of therapies can lead to better patient outcomes, including increased survival rates, enhanced quality of life, and better management of disease-related symptoms. The availability of many therapies encourages healthy market competition among pharmaceutical companies, leading to innovation, price competition, and improved treatment quality. For over four decades, the cornerstone of localized sarcoma treatment has involved surgical resection followed by neoadjuvant or adjuvant radiation or chemotherapy. However, even after completing surgical resection, approximately 50.0% of patients with intermediate or high-grade sarcoma develop metastatic disease. The advent of targeted therapy has brought about a paradigm shift in the treatment approach for sarcoma. Targeted therapies and upcoming breakthroughs in the pipeline will continue to play a pivotal role in driving market growth throughout the forecast period.

Rising Healthcare Awareness

There is a growing awareness among patients and healthcare providers regarding the incidence of liposarcoma. Both patients and doctors are actively engaging in learning about the available therapies for treating these severe diseases, leading to increased market opportunities. Increased awareness prompts patients to seek medical attention at earlier stages of the disease, leading to timely diagnosis and treatment initiation. Early detection can result in better treatment outcomes and potentially higher survival rates. Patients and healthcare providers who are more informed about available therapies can make more educated treatment decisions, leading to improved patient management and adherence to treatment plans. The increasing awareness about the incidence of liposarcoma among patients and healthcare providers creates a ripple effect that positively impacts diagnosis, treatment, research, advocacy, and market growth. As more attention is focused on this rare cancer, opportunities arise for collaboration, innovation, and improved patient care within the liposarcoma market.

Segmental Insights

Treatment Type Insights

The segment of anti-angiogenesis drugs is projected to experience rapid growth during the forecast period. This can be attributed to the growing demand for these drugs in cancer treatment. The prevalence of cancer and the necessity for effective therapies are driving factors behind this segment. Anti-angiogenesis drugs employ a molecular approach to hinder the formation of new blood vessels, which are essential for tumor growth and spread. This approach shows promise due to its relatively lower side effects compared to chemotherapy and radiation. In addition, the advent of innovative cancer treatments like immunotherapy and gene therapy is expected to contribute to the expansion of the anti-angiogenesis drugs segment. As these treatments become more accessible, the demand for anti-angiogenesis drugs is anticipated to rise. Plus, the increasing demand for personalized medicines is likely to create new opportunities for segment growth. However, the high cost of these treatments may impose limitations on the expansion of the anti-angiogenesis drugs segment.

End User Insights

Based on the end user segmentation, the market is categorized into hospitals, homecare, specialty centers, and others. The hospitals segment held the largest market share in 2023 and is projected to maintain its dominance throughout the forecast period. This can be attributed to increased government expenditure aimed at the development of the healthcare sector. Hospitals offer comprehensive treatment facilities for soft tissue sarcoma patients, including diagnostic imaging, surgical intervention, chemotherapy, radiation therapy, and supportive care services. These facilities allow for multidisciplinary collaboration among oncologists, surgeons, radiologists, pathologists, and other healthcare professionals, ensuring that patients receive integrated and coordinated care across all stages of their treatment journey.

Hospitals play a central role in the management of soft tissue sarcomas by providing specialized expertise, comprehensive treatment facilities, advanced medical technologies, access to clinical trials and research, and supportive care services. As a result, they are the primary setting where patients with soft tissue sarcomas receive diagnosis, treatment, and ongoing care, making hospitals the dominant end-user in the Global Soft Tissue Sarcoma Market.

Regional Insights

The demand for soft tissue sarcomas in North America is projected to experience substantial growth during the forecast period. This can be attributed to the rising incidence of this cancer type in the region, coupled with the availability of advanced treatment options. Likewise, the increasing emphasis on research and development of innovative therapies, including immunotherapies and targeted therapies, is anticipated to propel the demand for soft tissue sarcomas in North America. Also, the growing prevalence of personalized medicines and the presence of improved healthcare infrastructure in the region are expected to further drive the demand. However, it is important to note that the high cost of treatments may act as a limiting factor for the growth of this segment in the region.

Key Market Players

F. Hoffmann-La Roche Ltd.

Mylan N.V.

Teva Pharmaceutical Industries Ltd.

Sanofi S.A.

Pfizer Inc.

GSK plc

Novartis AG

Bayer AG

Sun Pharmaceutical Industries Ltd.

Merck Co., Inc.

Report Scope:

In this report, the Global Soft Tissue Sarcoma Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Soft Tissue Sarcoma Market,By Treatment Type:

• Targeted Therapy
• Chemotherapy
• Anti-Angiogenesis Drugs
• Radiation Therapy
• Others

Soft Tissue Sarcoma Market,By End User:

• Hospitals
• Homecare
• Specialty Centres
• Others

Soft Tissue Sarcoma Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Soft Tissue Sarcoma Market.

Available Customizations:

Global Soft Tissue Sarcoma marketreport with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1.Product Overview

• 1.1.Market Definition
• 1.2.Scope of the Market
  • 1.2.1.Markets Covered
  • 1.2.2.Years Considered for Study
  • 1.2.3.Key Market Segmentations

2.Research Methodology

• 2.1.Objective of the Study
• 2.2.Baseline Methodology
• 2.3.Key Industry Partners
• 2.4.Major Association and Secondary Sources
• 2.5.Forecasting Methodology
• 2.6.Data Triangulation Validations
• 2.7.Assumptions and Limitations

3.Executive Summary

• 3.1.Overview of the Market
• 3.2.Overview of Key Market Segmentations
• 3.3.Overview of Key Market Players
• 3.4.Overview of Key Regions/Countries
• 3.5.Overview of Market Drivers, Challenges, Trends

4.Voice of Customer

5.Clinical Trial Analysis

• 5.1.Ongoing Clinical Trials
• 5.2.Completed Clinical Trials
• 5.3.Terminated Clinical Trials
• 5.4.Breakdown of Pipeline, By Development Phase
• 5.5.Breakdown of Pipeline, By Status
• 5.6.Breakdown of Pipeline, By Study Application
• 5.7.Breakdown of Pipeline, By Region
• 5.8.Clinical Trials Heat Map

6.Global Soft Tissue Sarcoma Market Outlook

• 6.1.Market Size Forecast
  • 6.1.1.By Value
• 6.2.Market Share Forecast
  • 6.2.1.By Treatment Type (Targeted Therapy, Chemotherapy, Anti-Angiogenesis Drugs, Radiation Therapy, Others)
  • 6.2.2.By End User (Hospitals, Homecare, Specialty Centres, Others)
  • 6.2.3.By Region
  • 6.2.4.By Company (2023)
• 6.3.Market Map

7.North America Soft Tissue Sarcoma Market Outlook

• 7.1.Market Size Forecast
  • 7.1.1.By Value
• 7.2.Market Share Forecast
  • 7.2.1.ByTreatment Type
  • 7.2.2.By End User
  • 7.2.3.By Country
• 7.3.North America: Country Analysis
  • 7.3.1.United States Soft Tissue Sarcoma Market Outlook
    • 7.3.1.1.Market Size Forecast
      • 7.3.1.1.1.By Value
    • 7.3.1.2.Market Share Forecast
      • 7.3.1.2.1.By Treatment Type
      • 7.3.1.2.2.By End User
  • 7.3.2.Canada Soft Tissue Sarcoma Market Outlook
    • 7.3.2.1.Market Size Forecast
      • 7.3.2.1.1.By Value
    • 7.3.2.2.Market Share Forecast
      • 7.3.2.2.1.By Treatment Type
      • 7.3.2.2.2.By End User
  • 7.3.3.Mexico Soft Tissue Sarcoma Market Outlook
    • 7.3.3.1.Market Size Forecast
      • 7.3.3.1.1.By Value
    • 7.3.3.2.Market Share Forecast
      • 7.3.3.2.1.By Treatment Type
      • 7.3.3.2.2.By End User

8.Europe Soft Tissue Sarcoma Market Outlook

• 8.1.Market Size Forecast
  • 8.1.1.By Value
• 8.2.Market Share Forecast
  • 8.2.1.By Treatment Type
  • 8.2.2.By End User
  • 8.2.3.By Country
• 8.3.Europe: Country Analysis
  • 8.3.1.Germany Soft Tissue Sarcoma Market Outlook
    • 8.3.1.1.Market Size Forecast
      • 8.3.1.1.1.By Value
    • 8.3.1.2.Market Share Forecast
      • 8.3.1.2.1.By Treatment Type
      • 8.3.1.2.2.By End User
  • 8.3.2.United Kingdom Soft Tissue Sarcoma Market Outlook
    • 8.3.2.1.Market Size Forecast
      • 8.3.2.1.1.By Value
    • 8.3.2.2.Market Share Forecast
      • 8.3.2.2.1.By Treatment Type
      • 8.3.2.2.2.By End User
  • 8.3.3.Italy Soft Tissue Sarcoma Market Outlook
    • 8.3.3.1.Market Size Forecast
      • 8.3.3.1.1.By Value
    • 8.3.3.2.Market Share Forecast
      • 8.3.3.2.1.By Treatment Type
      • 8.3.3.2.2.By End User
  • 8.3.4.France Soft Tissue Sarcoma Market Outlook
    • 8.3.4.1.Market Size Forecast
      • 8.3.4.1.1.By Value
    • 8.3.4.2.Market Share Forecast
      • 8.3.4.2.1.By Treatment Type
      • 8.3.4.2.2.By End User
  • 8.3.5.Spain Soft Tissue Sarcoma Market Outlook
    • 8.3.5.1.Market Size Forecast
      • 8.3.5.1.1.By Value
    • 8.3.5.2.Market Share Forecast
      • 8.3.5.2.1.By Treatment Type
      • 8.3.5.2.2.By End User

9.Asia-Pacific Soft Tissue Sarcoma Market Outlook

• 9.1.Market Size Forecast
  • 9.1.1.By Value
• 9.2.Market Share Forecast
  • 9.2.1.By Treatment Type
  • 9.2.2.By End User
  • 9.2.3.By Country
• 9.3.Asia-Pacific: Country Analysis
  • 9.3.1.China Soft Tissue Sarcoma Market Outlook
    • 9.3.1.1.Market Size Forecast
      • 9.3.1.1.1.By Value
    • 9.3.1.2.Market Share Forecast
      • 9.3.1.2.1.By Treatment Type
      • 9.3.1.2.2.By End User
  • 9.3.2.India Soft Tissue Sarcoma Market Outlook
    • 9.3.2.1.Market Size Forecast
      • 9.3.2.1.1.By Value
    • 9.3.2.2.Market Share Forecast
      • 9.3.2.2.1.By Treatment Type
      • 9.3.2.2.2.By End User
  • 9.3.3.Japan Soft Tissue Sarcoma Market Outlook
    • 9.3.3.1.Market Size Forecast
      • 9.3.3.1.1.By Value
    • 9.3.3.2.Market Share Forecast
      • 9.3.3.2.1.By Treatment Type
      • 9.3.3.2.2.By End User
  • 9.3.4.South Korea Soft Tissue Sarcoma Market Outlook
    • 9.3.4.1.Market Size Forecast
      • 9.3.4.1.1.By Value
    • 9.3.4.2.Market Share Forecast
      • 9.3.4.2.1.By Treatment Type
      • 9.3.4.2.2.By End User
  • 9.3.5.Australia Soft Tissue Sarcoma Market Outlook
    • 9.3.5.1.Market Size Forecast
      • 9.3.5.1.1.By Value
    • 9.3.5.2.Market Share Forecast
      • 9.3.5.2.1.By Treatment Type
      • 9.3.5.2.2.By End User

10.South America Soft Tissue Sarcoma Market Outlook

• 10.1.Market Size Forecast
  • 10.1.1.By Value
• 10.2.Market Share Forecast
  • 10.2.1.By Treatment Type
  • 10.2.2.By End User
  • 10.2.3.By Country
• 10.3.South America: Country Analysis
  • 10.3.1.Brazil Soft Tissue Sarcoma Market Outlook
    • 10.3.1.1.Market Size Forecast
      • 10.3.1.1.1.By Value
    • 10.3.1.2.Market Share Forecast
      • 10.3.1.2.1.By Treatment Type
      • 10.3.1.2.2.By End User
  • 10.3.2.Argentina Soft Tissue Sarcoma Market Outlook
    • 10.3.2.1.Market Size Forecast
      • 10.3.2.1.1.By Value
    • 10.3.2.2.Market Share Forecast
      • 10.3.2.2.1.By Treatment Type
      • 10.3.2.2.2.By End User
  • 10.3.3.Colombia Soft Tissue Sarcoma Market Outlook
    • 10.3.3.1.Market Size Forecast
      • 10.3.3.1.1.By Value
    • 10.3.3.2.Market Share Forecast
      • 10.3.3.2.1.By Treatment Type
      • 10.3.3.2.2.By End User

11.Middle East and Africa Soft Tissue Sarcoma Market Outlook

• 11.1.Market Size Forecast
  • 11.1.1.By Value
• 11.2.Market Share Forecast
  • 11.2.1.By Treatment Type
  • 11.2.2.By End User
  • 11.2.3.By Country
• 11.3.MEA: Country Analysis
  • 11.3.1.South Africa Soft Tissue Sarcoma Market Outlook
    • 11.3.1.1.Market Size Forecast
      • 11.3.1.1.1.By Value
    • 11.3.1.2.Market Share Forecast
      • 11.3.1.2.1.By Treatment Type
      • 11.3.1.2.2.By End User
  • 11.3.2.Saudi Arabia Soft Tissue Sarcoma Market Outlook
    • 11.3.2.1.Market Size Forecast
      • 11.3.2.1.1.By Value
    • 11.3.2.2.Market Share Forecast
      • 11.3.2.2.1.By Treatment Type
      • 11.3.2.2.2.By End User
  • 11.3.3.UAE Soft Tissue Sarcoma Market Outlook
    • 11.3.3.1.Market Size Forecast
      • 11.3.3.1.1.By Value
    • 11.3.3.2.Market Share Forecast
      • 11.3.3.2.1.By Treatment Type
      • 11.3.3.2.2.By End User

12.Market Dynamics

• 12.1.Drivers
• 12.2.Challenges

13.Market Trends Developments

• 13.1.Merger Acquisition (If Any)
• 13.2.Product Launches (If Any)
• 13.3.Recent Developments

14.Porters Five Forces Analysis

• 14.1.Competition in the Industry
• 14.2.Potential of New Entrants
• 14.3.Power of Suppliers
• 14.4.Power of Customers
• 14.5.Threat of Substitute Products

15.Competitive Landscape

• 15.1.F. Hoffmann-La Roche Ltd.
  • 15.1.1.Business Overview
  • 15.1.2.Company Snapshot
  • 15.1.3.Products Services
  • 15.1.4.Financials (As Reported)
  • 15.1.5.Recent Developments
  • 15.1.6.Key Personnel Details
  • 15.1.7.SWOT Analysis
• 15.2.Mylan N.V.
• 15.3.Teva Pharmaceutical Industries Ltd.
• 15.4.Sanofi S.A.
• 15.5.Pfizer Inc.
• 15.6.GSK plc
• 15.7.Novartis AG
• 15.8.Bayer AG
• 15.9.Sun Pharmaceutical Industries Ltd.
• 15.10.Merck Co., Inc.

16.Strategic Recommendations

17.About Us Disclaimer